Results 51 to 60 of about 27,075 (224)

Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis

Frontiers in Oncology
Background and aimsImpaired double strand DNA repair by homologous repair deficiency (HRD) leads to sensitivity to poly ADP ribose polymerase (PARP) inhibition.
Sajjad Hajihosseini, Ehsan Emami, Seyed Amirali Zakavi, Parnia Jochin, Mehregan Shahrokhi, Sahar Khoshravesh, Mitra Goli, Mohaddeseh Belbasi, Gisou Erabi, Niloofar Deravi   +9 more
doaj   +1 more source

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells

Molecular Oncology, 2018
A number of prostate cancer (PCa)‐specific genomic aberrations (denominated BRCAness genes) have been discovered implicating sensitivity to PARP inhibition within the concept of synthetic lethality.
Gertrud E. Feiersinger, Kristina Trattnig, Peter D. Leitner, Fabian Guggenberger, Alexander Oberhuber, Sarah Peer, Martin Hermann, Ira Skvortsova, Jana Vrbkova, Jan Bouchal, Zoran Culig, Frédéric R. Santer   +11 more
doaj   +1 more source

Olaparib for advanced breast cancer

, 2020
Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared ...
Dieci M. V., Conte P., Guarneri V., Griguolo G., Miglietta F.   +4 more
core   +1 more source

Mitochondria‐Targeted Nanotherapeutics: A Promising Strategy in Modulating Mitochondrial Function, Transfer, and Transplantation

Advanced Science, EarlyView.
This review summarizes the pathogenic role of mitochondria in diseases and highlights mitochondrial transfer and transplantation as emerging therapeutic strategies. It systematically discusses how nanomaterials are engineered to facilitate these processes, and critically examines the current challenges and future perspectives for their clinical ...
Yuanyuan Su, Zhiyan Gong, Jiao Mu, Lili Huang, Pengfei Yang, Chenli Zhang, Lingshan Zhao, Liling Yang, Jun Deng, Xiaohui Liao   +9 more
wiley   +1 more source

A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer

Case Reports in Oncological Medicine, 2018
Olaparib was first FDA approved for use in women with advanced ovarian cancer and germline BRCA mutations. Based on the results of subsequent research, the use of this drug has been expanded to patients with metastatic breast cancer with germline BRCA ...
Megan Wheelden, Leah Cream, Jeffrey Sivik, Mark Robson   +3 more
doaj   +1 more source

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Journal for ImmunoTherapy of Cancer, 2018
Background Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with
Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge   +8 more
doaj   +1 more source

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis

BMC Cancer, 2023
Objective To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians.
Xiu Chen, Qinglian Wen, Liqiu Kou, Xiaolu Xie, Jun Li, Yaling Li   +5 more
doaj   +1 more source

NS1‐Induced PARP1 Phase Transitions Prolongs Host Transcriptional Pausing to Promote Influenza A Virus Replication

Advanced Science, EarlyView.
After IAV infection, NS1 induces PARP1 phase transition, reducing molecular mobility in condensates, prolonging host transcriptional pause, aiding RdRp cap snatching, and promoting viral transcription. ABSTRACT Influenza A virus (IAV) commandeers host transcriptional machinery to replicate, but mechanisms remain elusive.
Shufeng Ma, Changyuan Kang, Xixian Liu, Lichao Yang, Mengyi Li, Yuting Ye, Jianfang Zhang, Yingjun Li, Guanghui Jin, Yang Liu, Xiaohong Chen, Kexin Wang, Zifeng Yang   +12 more
wiley   +1 more source

AZD6738 overcomes acquired olaparib resistance in BRCA1 mutation triple-negative breast cancer through down-regulation of BRCA2 and RAD51

Scientific Reports
Although olaparib, a PARP inhibitor, has been approved for the treatment with triple-negative breast cancer (TNBC) harboring BRCA1/2 mutations, resistance inevitably emerges in TNBC patients.
Lei Huang, Ye Yang, Li Dai, Jinyue Zhou, Jialu Shao, Bingjun Qian   +5 more
doaj   +1 more source

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway

Cancer Biology & Therapy
Background Resistance to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) remain a major challenge in ovarian cancer (OC) treatment. However, the underlying mechanism of PARPi resistance is still poorly characterized.
Minxue Gai, Lanlan Zhao, Hongqi Li, Guoyu Jin, Wei Li, Fei Wang, Ming Liu   +6 more
doaj   +1 more source